The Bella Vista, Australia-based ResMed Inc (ASX: RMD) is a company established in 1994 and engaged in the development, production, and commercialization of medical devices and cloud-based software applications that diagnose, treat and manage chronic diseases like sleep apnea, chronic obstructive pulmonary disease, and others.
ResMed has a market capitalization of AUD 20.06 billion with approximately 1.43 billion outstanding shares. On February 22, 2019 (1:55 PM AEST), the RMD was trading at AUD 14.120, up by 0.86%, indicating an intra-day gain of AUD 0.120. The stock performance has undergone constant fluctuations through the last six months with a negative return yield of 3.78% as on 21 February 2019. The YTD return also remains negative at 12.72%. Although the trending stock price is closer to the 52-week high of AUD 16.570, the scenario for the future growth needs to be monitored.
As per the company’s report for the quarter ended December 31st, 2018, the net revenues were posted at USD 651.1 million, and the gross profit stood at USD 383.7 million, up on USD 349.8 million in the prior period. Also, the income from operations also increased to USD 157.1 million. As for the cash flows, the net cash derived from the operating activities stood at USD 177.6 million while the investing activities led to cash outflows of USD 806.41 million. Besides, the financing activities also resulted in cash inflows at USD 595.04 million. The net cash with the company at the end of the period stood at USD 149.47 million.
Mayne Pharma Group Limited
Mayne Pharma Group Limited (ASX: MYX) is a specialty pharmaceutical company, based out of Salisbury South, Australia, and manufactures and commercializes its products globally. It operates primarily through four business segments comprising Specialty Brands, Generic Products, Metrics Contract Services, and Mayne Pharma International.
The Group’s current market capitalization stands at AUD 1.27 billion, and it has approximately 1.58 billion outstanding shares. On 22 February 2019 (1:55 PM AEST), the MYX stock was trading at AUD 0.760, down by 5%, reflecting an intra-day decline of AUD 0.040. Although the average return yield generated by the stock for the last six months stands negative at 18.78%, the YTD return is reasonably positive at 7.38%. The stock price is trending more towards the 52-week low of AUD 0.650. Thus, the sentiment around MYX stock seems to be gaining a downward momentum, subject to the possibility of various developments capable of changing the scenario.
The company has been continuously employing strategies to repurpose existing drugs into new therapeutic areas. Recently, Mayne launched the LEXETTE™ (halobetasol propionate) Foam 0.05% and TOLSURA™ (SUBA®-itraconazole) 65mg capsule in the United States. During the FY2018, the company recorded a gross profit margin as a percentage of revenue at 48.4% (FY2017: 55.1%), indicating price deflation in the US generic market and various abnormal one-off items. Also, the reported loss before tax was posted at $ 164.3 million and the net loss after tax was $ 133.9 million. The company also had a net operating cash inflow of $ 121.5 million as compared to the cash outflows of $ 15.2 million in FY2017.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.